ReviewThe Journal of clinical and aesthetic dermatology2020
Topical Corticosteroid Therapy for Psoriasis-A Review of Clobetasol Propionate 0.025% Cream and the Clinical Relevance of Penetration Modification.
Review in The Journal of clinical and aesthetic dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 30 citations in OpenAlex.
- Topical clobetasol propionate 0.025% oral gel in the treatment of oral lichen planus: a double-blind, randomized placebo-controlled trial.BMC oral health · 2026Trial
- Topical Application of Frankincense Oil Extract Potently Ameliorates Psoriasis-like Dermatitis in Mice via Anti-Inflammatory and Skin Barrier-Protective Effects.International journal of molecular sciences · 2026Article
- A Multimodal Approach to Managing Severe Psoriasis Vulgaris: A Case Report Leveraging Natural Therapies for Flare Control.Life (Basel, Switzerland) · 2025Article
- Topical Therapy in Psoriasis: Clinical Benefits, Advances in Novel Drug Delivery Strategies, and Gene Therapy Regimen.Pharmaceutics · 2025Review
- Anti-Psoriatic Efficacies of Psorogrit and Divya-Taila, in Murine Models of Imiquimod and TPA-Induced Psoriasis-Like Inflammation are Driven by Modulation in IL-17RA/IL-23 and IL-8/TNF-α Signaling Axes.Journal of inflammation research · 2025Article
- Preparation of Patchouli Oil Microemulsion Gel and Its Topical Application to Ameliorate Atopic Dermatitis in Mice.Gels (Basel, Switzerland) · 2024Article
- A Multicenter Randomized Double-Blind Vehicle-Controlled Parallel Group Phase 2 Study Evaluating the Efficacy and Safety of GN-037 Cream in Patients with Mild-to-Moderate Plaque Psoriasis.Dermatology and therapy · 2024Article
- Evaluation of Clobetasol and Tacrolimus Treatments in an Imiquimod-Induced Psoriasis Rat Model.International journal of molecular sciences · 2024Article
- Attenuated effects of topical vinpocetine in an imiquimod-induced mouse model of psoriasis.Journal of Taibah University Medical Sciences · 2024Article
- The ameliorative effects of topical gemifloxacin alone or in combination with clobetasol propionate on imiquimod-induced model of psoriasis in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Advances in Immunosuppressive Agents Based on Signal Pathway.Frontiers in pharmacology · 2022Review
- Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Topical corticosteroids (TCs) have played a central role, over the past several decades, as a treatment for many dermatologic disorders. A number of factors, including potency, anticipated efficacy, vehicle formulation, and patient preference, directly influence the success or failure of any TC. In this article, the author reviews and discusses the current literature on various aspects of TCs for the treatment of plaque psoriasis, including an overview of product selection tendencies of patients, conventional use and formulations of topical clobetasol propionate (CP) 0.05%, and the use of special additives (e.g., penetration enhancers) to increase CP potency. The author highlights data from recent studies that evaluated a new CP cream formulation that incorporates half the concentration of traditional CP (0.025%) without the loss of super-potency (Class I) status and without the use of traditional potency enhancement with propylene glycol.
Indexed as
Identifiers
32308782PMC7158910W3026520269What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.